Latest Articles

There is a current lack of effective therapeutics with which to fight SARS-CoV-2. Could creating a "trick" version of the ACE2 receptor, the virus' entry point into cells, be the answer? We speak with Erik Procko to learn more about his research in this space.

With life science industries facing increased competition, global regulatory demands, and pressure to shorten time to market, outsourcing part – or all – manufacturing is becoming increasingly prevalent. But what should be considered in choosing such a custom or contract manufacturing partner?

What happens when you transiently turn "off" the gene that encodes ACE2, the protein that is required for SARS-CoV-2 to enter and infect cells? This is what Jamie Hackett and colleagues are currently exploring in animal models, to determine whether epigenetic silencing could be a treatment approach for COVID-19 in humans.

Researchers recently reported the development of a novel cancer vaccine. The vaccine is designed to target malignancies that express the transcription factor Wilms' tumor 1 (WT1) – a well characterized and highly immunogenic tumor‐associated antigen. Technology Networks had the pleasure of speaking with the project’s lead researcher, Associate Professor Kristen Radford to learn more about the CLEC9A-WT1 vaccine.

In an exclusive interview, Technology Networks spoke with Felix Breden, scientific manager at iReceptor Plus, to learn more about the iReceptor Plus Gateway – a repertoire of almost 200 million T and B cell receptor sequences from COVID-19 patients.

David A. Drew, of Massachusetts General Hospital and Harvard Medical School, explains, during the virtual COVID-19 and cancer meeting, how smartphone applications are able to facilitate the collection of self-reported data at scale. He discusses how data collected using the COVID-19 Symptom Study app has helped investigate COVID-19’s impact on racial and ethnic minority communities, and those living with cancer.

To keep the scientific community abreast of the continuous stream of new research data related to COVID-19 and cancer, on July 20, the American Association for Cancer Research (AACR) launched a three-day virtual COVID-19 and cancer meeting. Here, we highlight the main points discussed in the opening sessions.

Researchers are using sequencing technologies to rapidly expand our knowledge of the human microbiome and identify undiscovered bacterial genomes.

Technology Networks recently had the pleasure of speaking with Ewan St. John Smith, from the University of Cambridge, to learn more about the work his laboratory is conducting to determine the mechanisms behind the naked mole-rat’s exceptional resistance to cancer.

Testing has become a vital part of the response to the COVID-19 pandemic. In addition to the gold standard PCR tests used to detect currently infected individuals, a number of alternative antigen and antibody tests are also in development. In this article, we take a look at the differences between these tests and what they can tell us.